Synta Announces Presentations at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting
GALAXY – Trial design
“The
GALAXY Trial™ (NCT01348126): A Randomized 2b/3 Study of Ganetespib
(STA-9090) in Combination with Docetaxel versus Docetaxel Alone in
Subjects with Stage IIIB or IV NSCLC.” (Abstract: TPS7613^) –
Presenter:
Updated Phase 1 results – Ganetespib/docetaxel combination in solid tumors
“A
Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock
Protein 90 Inhibitor, in Combination with Docetaxel in Subjects with
Advanced Solid Tumor Malignancies.” (Abstract: 3094) –
Presenter:
Ganetespib activity in ALK- and ROS-driven cancer models
"Preclinical
Activity of the Hsp90 Inhibitor, Ganetespib, in ALK- and ROS1-Driven
Cancers.” (Abstract #3090) –
Presenter:
Ocular toxicity profiles of Hsp90 inhibitors
"Associating
Retinal Drug Exposure and Retention with the Ocular Toxicity Profiles of
Hsp90 Inhibitors." (Abstract #3086) –
Presenter:
About Ganetespib
Ganetespib is a potent, small-molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a molecular chaperone required for the proper folding and activation of many cancer-promoting proteins, and is recognized as a key facilitator of cancer cell growth and survival. In preclinical experiments, ganetespib has shown activity in multiple tumor models both as a single agent and in combination with certain widely used cancer agents. Ganetespib is currently being evaluated in a broad range of cancer clinical trials. In these trials, ganetespib has shown clinical activity in heavily pretreated patients and has been well tolerated to date with no evidence of severe liver or common ocular toxicities seen with other Hsp90 inhibitors. The most common adverse event seen to date has been transient, mild or moderate diarrhea, which has been manageable with standard supportive care. Information on clinical trials with ganetespib can be found at www.clinicaltrials.gov.
About
Source:
Synta Pharmaceuticals Corp.
George Farmer, 781-541-7125